Objective
Breakthrough gene expression search engine for cost reduction and significantly increased use of open data in drug discovery. We are putting the power of genetic data analytics into the cloud and providing this as an easy to access service to biologists via a search engine. The challenge today is that as the field of sequencing is developing at a rapid pace and the amount of genetic data is exploding, nobody really can analyze all that data and pull it up when needed for making informed decision in the field of drug development and life science research. We are seizing this business opportunity through our competitive edge by creating an easily usable cloud-based gene expression search engine on top of publicly available datasets that have been analyzed and indexed by our advanced algorithms. This allows for providing unexpected discoveries in the field of drug discovery at a significantly reduced rate and insight, which has not been possible before.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback.
You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Call for proposal
(opens in new window) H2020-SMEInst-2014-2015
See other projects for this callSub call
H2020-SMEINST-1-2014
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
10143 TALLINN
Estonia
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.